CervoMed (CRVO) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on treatments for age-related brain disorders, with lead candidate neflamapimod targeting neuroinflammation and synaptic dysfunction.

• Neflamapimod is in clinical development for dementia with Lewy Bodies (DLB), non-fluent variant primary progressive aphasia, stroke recovery, and ALS.

• Holds a new patent for neflamapimod in DLB patients without substantial AD-like tau pathology, providing IP protection into 2042.

Financial performance and metrics

• Closed a registered direct offering in June 2026, raising $10.0 million gross proceeds at $4.00 per share.

• Private Placement in June 2026 raised approximately $10.5 million gross proceeds at $3.14 per unit.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; proceeds from warrant exercises (if any) will be used for working capital and general corporate purposes.

• Potential proceeds from full cash exercise of Series B and C Warrants total approximately $21.8 million.